TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT05343013 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: TAS-102

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]